TY - JOUR
T1 - Movember GAP1 PDX project
T2 - An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models
AU - Navone, Nora M.
AU - van Weerden, Wytske M.
AU - Vessella, Robert L.
AU - Williams, Elizabeth D.
AU - Wang, Yuzhuo
AU - Isaacs, John T.
AU - Nguyen, Holly M.
AU - Culig, Zoran
AU - van der Pluijm, Gabri
AU - Rentsch, Cyril A.
AU - Marques, Rute B.
AU - de Ridder, Corrina M.A.
AU - Bubendorf, Lukas
AU - Thalmann, George N.
AU - Brennen, William Nathaniel
AU - Santer, Frédéric R.
AU - Moser, Patrizia L.
AU - Shepherd, Peter
AU - Efstathiou, Eleni
AU - Xue, Hui
AU - Lin, Dong
AU - Buijs, Jeroen
AU - Bosse, Tjalling
AU - Collins, Anne
AU - Maitland, Norman
AU - Buzza, Mark
AU - Kouspou, Michelle
AU - Achtman, Ariel
AU - Taylor, Renea A.
AU - Risbridger, Gail
AU - Corey, Eva
N1 - Funding Information:
The authors thank the patients and their families. With great appreciation, we acknowledge their altruism that made establishment of these models possible for studies to alleviate the suffering and death associated with prostate cancer for fathers, sons, brothers, and husbands around the world. The financial support for this study was provided by the Movember Foundation, as a project of the Global Action Plan 1 (GAP1) PDX project. We would also like to thank all GU Cancer Research Laboratory at the University of Washington personnel, mainly Janna Quinn, Kent Buhler, Daniel Sondheim, Lisha Brown, Bryce Lakely, and many other for outstanding technical support throughout the years, the pathologists Lawrence True, and Martine Roudier, all oncologists who were involved in the patients enrollment, and Sarah Holt for statistical analyses; Charles Kulkarni at the Department of Legal Services of The University of Texas MD Anderson Cancer Center for developing the collaborative agreement for the sharing of specimens between participating institutions and distribution of the TMAs to scientists; the Stanford Alexander Tissue Derivative Laboratory of the David H. Koch Center for Applied Research of Genitourinary Cancers at MD Anderson Cancer Center, in particular Anh G. Hoang for the building of the TMAs; Hans Stoop and Arno van Leeders at the Department of Pathology at Erasmus MC for the IHC staining and pathological assessment; Allison Eckert at Australian Prostate Cancer Bioresource, Australian Prostate Cancer Research Centre-Queensland for managing tissue donation; John Pedersen and Michelle Richards at Monash University and Geertje van der Horst at Leiden University for technical assistance. We would like to acknowledge Marco G. Cecchini, who passed away after short illness. He will be remembered for his scientific approach, integrity, and knowledge as well as his wit and kind personality.
Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.
AB - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.
KW - PDX
KW - patient-derived xenograft
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85052433082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052433082&partnerID=8YFLogxK
U2 - 10.1002/pros.23701
DO - 10.1002/pros.23701
M3 - Article
C2 - 30073676
AN - SCOPUS:85052433082
SN - 0270-4137
VL - 78
SP - 1262
EP - 1282
JO - Prostate
JF - Prostate
IS - 16
ER -